Project Grant R01DK148554
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $835K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $156,510 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on July 1, 2026. The project, "Precision Metabolic Risk Stratification in Depression Via Multi-Omics and EHR," addresses the elevated type 2 diabetes risk in individuals with major depressive disorder, particularly those treated with selective...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $842,732 on July 8, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate pathway-specific polygenic scores that predict individual metabolic responses to weight loss interventions. The award funds research testing whether pathway-specific polygenic scores (PPGSs) can identify biological pathways that modify how...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $123,750 to Massachusetts General Hospital on February 4, 2026, for development of an audio-based digital intervention to improve diabetes medication adherence among Latino adults with low health literacy. The recipient, The General Hospital Corporation (doing business as Massachusetts General Hospital), will develop AudibleDiabetesRx, an audio-based tool delivering on-demand, Spanish-language medication information...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $158,696 on January 17, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research investigating the role of intestinal fibrosis in Hirschsprung disease. The research characterizes cellular and molecular features of the aganglionic bowel segment and tests anti-fibrotic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation $561,565 on July 30, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a Project Grant (R01DK145514) investigating the molecular mechanisms by which testican-2 protects against chronic kidney disease. The award funds research establishing the protective effect of circulating testican-2 in clinically relevant kidney disease...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $990,000 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a pilot study testing whether polygenic architecture can inform targeted screening and treatment strategies for type 1 and type 2 diabetes. The research implements a genetics-first, recall-by-genotype framework embedded in...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), a Harvard Medical School-affiliated academic medical center, received a $201,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective August 1, 2025, through July 31, 2027. This R03 award supports a discrete, well-defined research project that expands upon a parent...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $197,320 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support career development and investigator-initiated research in glycemic monitoring and management. The award funds research by Dr. Mengyao Tang, a board-certified nephrologist at Massachusetts General Hospital, to...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $158,960 on September 30, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct genetic research on taste preferences and their relationship to metabolic disease risk and GLP-1 receptor agonist response. The research will perform genome-wide association studies of five taste preferences, apply Mendelian randomization and polygenic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $850,096 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of S100A9+ macrophages and monocytic myeloid-derived suppressor cells in driving liver fibrosis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The research leverages advanced multi-omics...